Status:
NOT_YET_RECRUITING
NOTIFY (New Observations Taking Information From Yesterday)
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Duke University
Patient-Centered Outcomes Research Institute
Conditions:
Atherosclerotic Cardiovascular Disease
Eligibility:
All Genders
50-84 years
Phase:
NA
Brief Summary
This trial will investigate whether notifying patients and their clinicians of the presence of moderate or severe coronary artery calcium on a low-dose CT scan performed for lung cancer screening resu...
Eligibility Criteria
Inclusion
- Age \>=18 years
- No known ASCVD
- Lung cancer screenee with low dose CT scan (LDCT) within the last 5 years
- Coronary artery calcium (CAC) score on LDCT \>100 Agatston units (AU)
- Not taking a statin or other lipid-lowering therapy (e.g., ezetimibe, bempedoic acid, or PCSK9-lowering therapy)
Exclusion
- Dementia or other neuropsychiatric disorder that interferes with medication adherence
- CAC scan, coronary CT angiogram, or invasive angiogram since LDCT
- Statin medication intolerance or allergy
- Life expectancy \<2 years, e.g., metastatic cancer or active cancer undergoing chemotherapy
Key Trial Info
Start Date :
March 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2032
Estimated Enrollment :
40000 Patients enrolled
Trial Details
Trial ID
NCT05977413
Start Date
March 1 2026
End Date
June 1 2032
Last Update
November 25 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.